STAT+: Pharmalittle: J&J to split into two companies; AstraZeneca will price its Covid-19 vaccine to make it profitable
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather modest. We plan to promenade with the official mascot, catch up on our reading, tidy around the castle, and take a nap or three. And what about you? This remains a fine time to enjoy the great outdoors — think of the varied leaf colors. You could also boost the economy and order a few holiday gifts. Or convince some of the holdouts to get vaccinated. Well, whatever you do, have a grand time, but be safe. Enjoy, and see you soon. …
Johnson & Johnson (JNJ) plans to break up into two companies, splitting off the $15-billion-a-year division that sells Band-Aid bandages, Tylenol medicines and Johnson’s Baby Powder in a shift indicating how health care has changed since the company helped pioneer the industry, The Wall Street Journal reports. The move, which will occur in 18 to 24 months, will separate its high-margin but risky prescription-drugs and medical-devices business from its storied but slower-growing consumer group, creating two publicly traded companies. What form the separation will take, what the new company will be called, and who will lead it are yet to be worked out.
Continue to STAT+ to read the full story…
